Exelixis Inc (NASDAQ: EXEL)’s stock price has decreased by -7.43 compared to its previous closing price of 36.43. However, the company has seen a -5.40% decrease in its stock price over the last five trading sessions. fxempire.com reported 2025-01-22 that Shares of oncology company Exelixis, Inc. (EXEL) gaining on rising revenue, pipeline progress.
Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?
Exelixis Inc (NASDAQ: EXEL) has a price-to-earnings ratio of 21.49x that is above its average ratio. Additionally, the 36-month beta value for EXEL is 0.54. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for EXEL is 278.50M and currently, short sellers hold a 3.75% ratio of that float. The average trading volume of EXEL on January 22, 2025 was 2.27M shares.
EXEL’s Market Performance
EXEL stock saw an increase of -5.40% in the past week, with a monthly gain of 0.19% and a quarterly increase of 16.70%. The volatility ratio for the week is 2.91%, and the volatility levels for the last 30 days are 2.71% for Exelixis Inc (EXEL). The simple moving average for the last 20 days is -2.58% for EXEL stock, with a simple moving average of 24.28% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with BMO Capital Markets repeating the rating for EXEL by listing it as a “Market Perform.” The predicted price for EXEL in the upcoming period, according to BMO Capital Markets is $40 based on the research report published on December 20, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $39, previously predicting the price at $35. The rating they have provided for EXEL stocks is “Neutral” according to the report published on December 17th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to EXEL, setting the target price at $34 in the report published on October 16th of the previous year.
EXEL Trading at -3.81% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.28% of loss for the given period.
Volatility was left at 2.71%, however, over the last 30 days, the volatility rate increased by 2.91%, as shares surge +0.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.55% lower at present.
During the last 5 trading sessions, EXEL fell by -4.92%, which changed the moving average for the period of 200-days by +44.30% in comparison to the 20-day moving average, which settled at $34.63. In addition, Exelixis Inc saw 1.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXEL starting from Hessekiel Jeffrey, who sale 60,000 shares at the price of $36.67 back on Nov 29 ’24. After this action, Hessekiel Jeffrey now owns 486,059 shares of Exelixis Inc, valued at $2,200,200 using the latest closing price.
JEFFREY HESSEKIEL, the Officer of Exelixis Inc, proposed sale 60,000 shares at $36.67 during a trade that took place back on Nov 29 ’24, which means that JEFFREY HESSEKIEL is holding shares at $2,200,230 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.96 for the gross margin
The net margin for Exelixis Inc stands at 0.22. The total capital return value is set at 0.2. Equity return is now at value 20.20, with 15.73 for asset returns.
Based on Exelixis Inc (EXEL), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 2.42. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 19.91.
Currently, EBITDA for the company is 196.6 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 4.63. The receivables turnover for the company is 7.72for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.93.
Conclusion
In conclusion, Exelixis Inc (EXEL) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
